Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02836652 · ClinicalTrials.gov registry record · Phase 4
Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy
A Phase 4 study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- Phase 4
- Development phase
- 72
- Enrollment target
NCT02836652 is a Phase 4 study that has completed, run by Abbott Medical Devices. The registered enrollment target is 72 participants.
The verdict
NCT02836652, a Phase 4 study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study is a prospective, multi-center, randomized, double-blind placebo-controlled study of subjects receiving the HM II LVAD as per the current FDA approved indications for use.
Interventions
- DRUG Warfarin
- DEVICE HeartMate II (HMII)
- DRUG acetylsalicylic acid (ASA) therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2016-11 |
| Est. Completion | 2019-07-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02836652
The ClinicalTrials.gov registry entry for NCT02836652 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Medical Devices, which has 261 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.
NCT02836652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02836652 about?
NCT02836652 is a clinical study titled "Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy". This study is a prospective, multi-center, randomized, double-blind placebo-controlled study of subjects receiving the HM II LVAD as per the current FDA approved indications for use.
What is the current status of trial NCT02836652?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 72 participants. The study started on 2016-11. Estimated completion is 2019-07-18.
What interventions are being tested in trial NCT02836652?
The interventions under investigation include: Warfarin (DRUG), HeartMate II (HMII) (DEVICE), acetylsalicylic acid (ASA) therapy (DRUG).
Who is sponsoring clinical trial NCT02836652?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.